Products with Hepatoprotective bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN2165 | Agomelatine |
| Agomelatine is a competitive antagonist of human and porcine serotonin (5-HT2C) receptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6). Agomelatine is a melatonin (MT) analogue with agonistic properties and has been proven to be effective for various types of depressive symptoms, agomelatine also has anticonvulsant activity. Agomelatine treatment could represent a novel useful approach to the clinical care of subjects with Chronic Fatigue Syndrome (CFS). Agomelatine administration protects liver cells from paracetamol-induced hepatotoxicity via antioxidant activity and reduced proinflammatory cytokines, such as TNF-α and IL-6. | |
| BCN2196 | Melatonin |
| Melatonin, a hormone produced in the brain, is a potent melatonin receptor activator, and possesses important anti-cancer, antioxidative and anti-inflammatory properties, it can reduce lead toxicity in vivo and in vitro. Melatonin may be useful as a pharmacological agent to protect against hepatic metabolic diseases due to its ability to regulate expression of miR-23a. | |
| BCN2225 | Thiamine hydrochloride |
| Thiamine hydrochloride is an efficient catalyst for the synthesis of amidoalkyl naphthols, it has prophylactic potential on lead induced lipid peroxidation in rat liver and kidney. Thiamine hydrochloride complex as a new anti-diabetic candidate. | |
| BCN2231 | S-Adenosyl-L-Methtonine |
| 1. S-Adenosyl-L-methionine, L-methionine, and N-acetylcysteine exert various degrees of protection toward ethanol-induced cell injury, which are related to the efficiency of these compounds in maintaining a high glutathione pool. | |
| BCN2271 | Gomisin N |
| Gomisin N has anti-oxdiant, anti-inflammatory, anti-cancer and anti-hepatitis activities; it produces beneficial sedative and hypnotic bioactivity, which may be mediated by the modification of the serotonergic and GABAergic system. Gomisin N can enhance TNF-α-induced apoptosis by suppressing of NF-κB and EGFR signaling pathways, and potentiate TRAIL-induced apoptosis through ROS-mediated up-regulation of death receptors 4 and 5. | |
